# To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01785433** · PHASE1,PHASE2 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 36 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Tiotropium HFA BAI 4.5 mcg
- **DRUG:** Tiotropium HFA BAI 9.0 mcg
- **DRUG:** SPIRIVA® HandiHaler® 18 mcg/day
- **DRUG:** Spiriva® Respimat® 5 mcg/day

## Key facts

- **NCT ID:** NCT01785433
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-07
- **Final completion:** 2013-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01785433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01785433, "To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01785433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*